Moreover, this study is the first to have evaluated the prevalence and associated factors for HS, a concept only recently introduced by the ESC, in T2DM patients with concomitant hypertension/high-normal BP and T2DM, eligible for SGLT2i and GLP1-RA, drugs that have been found to exert several benefits on cardiac dysfunction. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.